Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

1435003

USP

6α-Methylprednisolone

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

6α-Methylprednisolone, 11β,17α,21-Trihydroxy-6α-methyl-1,4-pregnadiene-3,20-dione, 6α-Methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione, Medrol, Medrone

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C22H30O5
Número de CAS:
83-43-2
Peso molecular:
374.47
Beilstein:
2340300
Número MDL:
MFCD00010591
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329750457
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

methylprednisolone

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

Clave InChI

VHRSUDSXCMQTMA-PJHHCJLFSA-N

Información sobre el gen

human ... NR3C1(2908)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Methylprednisolone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Methylprednisolone Sodium Succinate for Injection
  • Methylprednisolone Tablets

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

1437009

Methylprednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard

M1750000

6α-Methylprednisolone, European Pharmacopoeia (EP) Reference Standard

M1755200

Methylprednisolone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard

M1755220

Methylprednisolone hydrogen succinate for performance test, European Pharmacopoeia (EP) Reference Standard

M1755000

Methylprednisolone acetate, European Pharmacopoeia (EP) Reference Standard

1436006

Methylprednisolone acetate, United States Pharmacopeia (USP) Reference Standard

PHR1718

Methylprednisolone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001759

Methylprednisolone hydrogen succinate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001736

Methylprednisolone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001760

Methylprednisolone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001799

6α-Methylprednisolone, European Pharmacopoeia (EP) Reference Standard

1435036

Methylprednisolone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1435014

Methylprednisolone Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP248

6α-Methylprednisolone, British Pharmacopoeia (BP) Reference Standard

BP249

Methylprednisolone acetate, British Pharmacopoeia (BP) Reference Standard

BP572

Deltamedrane, British Pharmacopoeia (BP) Reference Standard

1437042

Methyl Prednisolone Hemisuccinate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1437020

Methylprednisolone Hemisuccinate Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR3043

Methylprednisolone Related Compound C, pharmaceutical secondary standard, certified reference material

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H360FD,H373

Clasificaciones de peligro

Repr. 1B - STOT RE 2

Órganos de actuación

Adrenal gland,Immune system

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 2

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Robert J Fox et al.
Neurology, 82(17), 1491-1498 (2014-04-01)
RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. Eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. Patients
Amy L Samuels et al.
British journal of haematology, 165(1), 57-66 (2014-01-25)
Drug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children. Up to 25% of patients with T-cell ALL (T-ALL) develop resistance to chemotherapeutic agents, particularly to glucocorticoids (GCs), a class of drug to
M Toledano et al.
Neurology, 82(18), 1578-1586 (2014-04-08)
To evaluate a trial of immunotherapy as an aid to diagnosis in suspected autoimmune epilepsy. We reviewed the charts of 110 patients seen at our autoimmune neurology clinic with seizures as a chief complaint. Twenty-nine patients met the following inclusion
Tyree H Kiser et al.
American journal of respiratory and critical care medicine, 189(9), 1052-1064 (2014-03-13)
Studies evaluating corticosteroid (CS) dosing for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have largely excluded patients admitted directly to the intensive care unit (ICU), and none have evaluated the effect of CS dosing regimens
Emilio Portaccio et al.
Journal of neurology, neurosurgery, and psychiatry, 85(8), 845-850 (2014-01-10)
To assess relapses, disability progression and the role of disease modifying drugs (DMDs) in the year after delivery in women with multiple sclerosis (MS). We prospectively followed-up pregnancies occurring between 2002 and 2008 in women with MS, recruited from 21
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico